BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31514959)

  • 21. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
    Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cystic pancreatic tumors: diagnostics and new biomarkers].
    Berger AW; Seufferlein T; Kleger A
    Chirurg; 2017 Nov; 88(11):905-912. PubMed ID: 28831506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
    Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
    Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
    Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
    J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraductal Papillary Mucinous Neoplasms of the Pancreas: Correlation of Helical Computed Tomography (CT) Features With Pathologic Findings.
    Xu W; Liu X; Zhang J; Yang L
    Acad Radiol; 2017 May; 24(5):609-614. PubMed ID: 28153575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal papillary mucinous neoplasm: a case report.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Kono H; Nagayoshi Y; Shindo K; Ushijima Y; Ueda J; Takahata S; Ito T; Oda Y; Mizumoto K; Tanaka M
    JOP; 2013 Jul; 14(4):450-3. PubMed ID: 23846946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer.
    Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J
    Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
    Kamata K; Kitano M; Kudo M; Sakamoto H; Kadosaka K; Miyata T; Imai H; Maekawa K; Chikugo T; Kumano M; Hyodo T; Murakami T; Chiba Y; Takeyama Y
    Endoscopy; 2014 Jan; 46(1):22-9. PubMed ID: 24218310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.
    Berger AW; Schwerdel D; Reinacher-Schick A; Uhl W; Algül H; Friess H; Janssen KP; König A; Ghadimi M; Gallmeier E; Bartsch DK; Geissler M; Staib L; Tannapfel A; Kleger A; Beutel A; Schulte LA; Kornmann M; Ettrich TJ; Seufferlein T
    Theranostics; 2019; 9(5):1280-1287. PubMed ID: 30867830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
    Luo X; Liu J; Wang H; Lu H
    Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm.
    Nakagawa T; Masuda A; Toyama H; Shiomi H; Zen Y; Sofue K; Takenaka M; Kobayashi T; Yagi Y; Yamanaka K; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Ku Y; Azuma T
    Pancreas; 2017 Apr; 46(4):582-588. PubMed ID: 28099253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
    Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
    J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm.
    Ikegawa T; Masuda A; Sakai A; Toyama H; Zen Y; Sofue K; Nakagawa T; Shiomi H; Takenaka M; Kobayashi T; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Azuma T
    Pancreatology; 2018 Jun; 18(4):399-406. PubMed ID: 29685673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer.
    Ilies M; Sappa PK; Iuga CA; Loghin F; Gesell Salazar M; Weiss FU; Beyer G; Lerch MM; Völker U; Mayerle J; Hammer E
    Clin Chim Acta; 2018 Feb; 477():127-134. PubMed ID: 29221926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
    Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
    Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.